

HPV Module RESOURCES

Publications

1. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. *Brit J Cancer* 2003;88: 63–73.
2. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. *Vaccine*. 2006;31;24 Suppl 3:S3/11–25.
3. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. *Cancer Epidemiol Biomarkers Prev*. 2005;14(2):467–75.
4. Garland SM, Steban M, Sings HL, James M et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase II trials of a quadrivalent human papillomavirus (Types 6, 11, 16, and 18) Vaccine. *J Infect Dis* 2009;1999:805–14.
5. Moscicki AB, Shibuski S, Broering J, Powell K, Clayton L, Jay N et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. *J Pediatr* 1998;132(2):277–284.
6. Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. *J Natl Cancer Inst* 1995;87(18):1365–1371.
7. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. *Am J Epidemiol*. 2003;157(3):218–26.
8. Partridge JM, Hughes JP, Feng Q, Winer RL, Weaver BA, Xi LF, et al. Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. *J Infect Dis*. 2007;196(8):1128–36.
9. Hernandez BY, Wilkens LR, Zhu X, Thompson P, McDuffie K, Shvetsov YB, et al. Transmission of human papillomavirus in heterosexual couples. *Emerg Infect Dis* 2008;14(6):888–94.
10. Burchell AN, Tellier PP, Hanley J, Coutlée F, Franco EL. Human papillomavirus infections among couples in new sexual relationships. *Epidemiol* 2010;21(1):31–7.
11. D'Souza G, Fakhry C, Sugar EA, Seaberg EC, Weber K, Minkoff HL, et al. Six-month natural history of oral versus cervical human papillomavirus infection. *Int J Cancer*. 2007;121(1):143–50.
12. Oriel JD. Natural History of genital warts. *Br J Vener Dis* 1971;47:1–13.
13. CDC. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER.. Quadrivalent Human Papillomavirus Vaccine, Recommendations of the Advisory Committee for Immunization Practices (ACIP) *MMWR* 2007;56(RR02):1–24.
14. CDC. FDA Licensure of Bivalent Human Papillomavirus Vaccine (HPV2, Cervarix) for Use in Females and Updated HPV Vaccination Recommendations from the Advisory Committee on Immunization Practices (ACIP). *MMWR* 2010;59(20):626–629.
15. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. *N Engl J Med* 2007;356(19):1928–1943.
16. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. *N Engl J Med* 2007;356(19):1915–1927.
17. Food and Drug Administration, Product approval information—licensing action, package insert: Gardasil (quadrivalent human papillomavirus types 6, 11, 16 and 18 HPV),

- Merck & Co. Whitehouse Station, NJ: Food and Drug Administration; 2009. Accessed March 23, 2010. Available at:
<http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM111263.pdf>
18. Food and Drug Administration, Product approval information—licensing action, package insert: Cervarix (Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant), GlaxoSmithKline Biologicals Whitehouse Station, NJ: Food and Drug Administration; 2009. Accessed April 23, 2010. Available at:<http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM186981.pdf>
19. CDC. [FDA Licensure of Quadrivalent Human Papillomavirus Vaccine \(HPV4, Gardasil\) for Use in Males and Guidance from the Advisory Committee on Immunization Practices \(ACIP\)](#). MMWR 2010;59(20):630–632.
20. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr, Aranda C, Jessen H, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. *N Engl J Med*. 2011 Oct 27;365(17):1576–85.
21. Nyitray AG, Carvalho da Silva RJ, Baggio ML, Smith D, Abrahamsen M, Papenfuss M, et al. Six-Month Incidence, Persistence, and Factors Associated With Persistence of Anal Human Papillomavirus in Men: The HPV in Men Study. *J Infect Dis*. 2011 Dec;204(11):1711–22. Epub 2011 Sep 30.
22. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Penny ME, Aranda C, et al. Efficacy of Quadrivalent HPV vaccine against HPV infection and disease in males. *New Engl J Med* 2011;364:401–412.
23. CDC. Cervical cancer screening recommendations. Available at:
<http://www.cdc.gov/cancer/cervical/pdf/guidelines.pdf>
24. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. *J Natl Cancer Inst* 2005;97(14):1072–9.
25. Jain N, Irwin K, Carlin L, Freeman C, Montano D, Kasprzyk D. Use of DNA tests for human Papillomavirus infection by US clinicians, 2004. *J Infect Dis*. 2007;196(1):76–81.
26. Moriarty AT, Schwartz MR, Eversole G, Means M, Clayton A, Souers R, et al. Human papillomavirus testing and reporting rates: practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Gynecologic Cytology in 2006. *Arch Pathol Lab Med*. 2008;132(8):1290–4.
27. Solomon D, Schiffman M, Tarone R; ALTS Study group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. *J Natl Cancer Inst*. 2001 Feb 21;93(4):293–9.
28. Widdice LE, Moscicki AB. Updated guidelines for Papanicolaou tests, colposcopy, and human papillomavirus testing in adolescents. *J Adolesc Health*. 2008;43(4 Suppl):S41–51.
29. Food and Drug Administration, Product approval information—licensing action, package insert. VEREGEN™ (Kunecatechins) Ointment, 15% Accessed April 23, 2010. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021902lbl.pdf
30. Tatti S, Swinehart JM, Thielert C, Tawfik H, Mescheder A, Beutner KR. Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts. *Obstet Gyn* 2008;111:1371–9.

31. Stockfleth E, Beti H, Orasan R, Grigorian F, Mescheder A, Tawfik H, et al. Topical Polyphenon® E in the treatment of external genital and perianal warts: A randomized controlled trial. *Br J Derm* 2008;158:1329–1338.
32. Gross G, Meyer KG, Pres H, Thieler C, Tawfik H, Mescheder A. A randomized, double-blind, four-arm parallel-group, placebo-controlled Phase II/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon E in the treatment of external genital warts. *J Europ Acad Derm Vener* 2007;21:1404–1412.
33. Mashiah J, Brenner S. Possible mechanisms in the induction of vitiligo-like hypopigmentation by topical imiquimod. *Clinic Experiment Derm* 2007;33:74–76.
34. Gotovtsheva EP, Kapadia AS, Smolensky MH, Lairson DR. Optimal Frequency of Imiquimod (Aldara) 5% Cream for the treatment of external genital warts in immunocompetent adults: a meta-analysis. *Sex Transm Dis* 2008;35:346–351.
35. Garland SM, Waddell R, Mindel A, Denham IM, McCloskey JC. An open-label phase II pilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in women. *Int J STD AIDS* 2006;17:448–52.
36. Dolev JC, Maurer T, Springer G, Glesby MJ, et al. Incidence and risk factors for verrucae in women. *AIDS* 2008;19:1213–9.
37. De Panfilis G, Melzani G, Mori G, Ghidini A, Graifemberghi S. Relapses after treatment of external genital warts are more frequent in HIV-positive patients than in HIV-negative controls. *Sex Transm Dis* 2002;29:121–5.
38. Silverberg MJ, Ahdieh L, Munoz A, et al. The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts. *Sex Transm Dis* 2002;29:427–35.
39. Chiao EY, Giordano TP, Palefsky JM, Tyring S, El Serag H. Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review. *Clin Infect Dis* 2006; 43(2):223–33.
40. CDC. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H; Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. [Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.](#) MMWR Recomm Rep. 2009;58(RR-4):1–207.
41. Graziottin A, Serafini A. HPV infection in women: psychosexual impact of genital warts and intraepithelial lesions. *J Sex Med.* 2009;Mar;6(3):633–45.
42. McCaffery K, Waller J, Nazroo J, Wardle J. Social and psychological impact of HPV testing in cervical screening: a qualitative study. *Sex Transm Infect.* 2006;82(2):169–74.
43. Perrin KK, Daley EM, Naoum SF, Packing-Ebuen JL, Rayko HL, McFarlane M, et al. Women's reactions to HPV diagnosis: insights from in-depth interviews. *Women Health* 2006;43(2):93–110.
44. Friedman A, Shepeard H. Exploring the Knowledge, attitudes, beliefs, and communication preferences of the general public regarding HPV: findings from CDC focus group research and implications for practice. *Health Education and Behavior* 2007; Jan 3.
45. Reitano M. (1997). Counseling patients with genital warts: Perspectives on Human Papillomavirus Infection. *Am J Med* 102(5A Supplement): 38–43.
46. Linnehan MJ, Groce NE. Counseling and educational interventions for women with genital human papillomavirus infection. *AIDS Patient Care STDS.* 2000;14(8):439–45.

47. Kahn JA, Lan D, Kahn RS. Sociodemographic factors associated with high-risk human papillomavirus infection. *Obstet Gynecol*. 2007 Jul;110(1):87–95. Erratum in: *Obstet Gynecol*. 2007;110(3):713.
48. Winer RL, Hughes JP, Feng Q, O'Reilly S, Kiviat NB, Holmes KK, et al. Condom use and the risk of genital human papillomavirus infection in young women. *N Engl J Med*. 2006;354(25):2645–5.
49. Hogewoning CJ, Bleeker MC, van den Brule AJ, Voorhorst FJ, Snijders PJ, Berkhof J, et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. *Int J Cancer*. 2003;107(5):811–6.
50. Bleeker MC, Hogewoning CJ, Voorhorst FJ, van den Brule AJ, Snijders PJ, Starink TM, et al. Condom use promotes regression of human papillomavirus-associated penile lesions in male sexual partners of women with cervical intraepithelial neoplasia. *Int J Cancer*. 2003 Dec 10;107(5):804–10.
51. Satterwhite CL, et al. Sexually transmitted infections among U.S. women and men: Prevalence and incidence estimates, 2008. *Sex Transm Dis* 2013;40(3): pp. 187-193
52. Owusu-Edusei K, et al. The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. *Sex Transm Dis* 2013;40(3): pp. 197-201.

Websites and Other Resources

1. CDC Division of STD Prevention: www.cdc.gov/std
2. 2010 CDC STD Treatment Guidelines (including E-book downloadable version): www.cdc.gov/STD/treatment/2010/
3. National Network of STD/HIV Prevention Training: Centers: nnptc.org/
4. STD information and referrals to STD clinics:
CDC-INFO
1-800-CDC-INFO (800-232-4636)
TTY: 1-888-232-6348
In English, en Español
5. CDC National Prevention Information Network (NPIN): www.cdcnpin.org
6. American Sexual Health Association, National HPV and Cervical Cancer Prevention Resource Center: www.ashastd.org/std-sti/hpv.html
7. CDC Cervical Cancer and Pap Test Information: www.cdc.gov/cancer/cervical/pdf/cc_basic.pdf
8. National Cancer Institute (NCI): www.cancer.gov/
9. U.S. Preventive Services Task Force Cervical Cancer Screening: Recommendations: www.uspreventiveservicestaskforce.org/uspstf/uspscerv.htm
10. American College of Obstetrics and Gynecology: www.acog.org
11. American Society of Colposcopy and Cervical Pathology (ASCCP): www.asccp.org
12. CDC Advisory Committee on Immunization Practices: www.cdc.gov/vaccines/acip/index.html
13. American Cancer Society: www.cancer.org/Cancer/CervicalCancer/index